OBJECTIVE: In this study, the hormone profile, lipid profile, and inflammatory parameters of patients with polycystic ovary syndrome were compared with those of non-polycystic ovary syndrome patients to determine predictive markers in young polycystic ovary syndrome patients who have not yet had children. METHODS: Patients' age, height, weight, body mass index, waist circumference, degree of hirsutism, and ultrasound findings were recorded. Hormone profile, lipid levels, ratio of complete blood count parameters, monocyte/high-density lipoprotein ratio, and total cholesterol/high-density lipoprotein ratio were compared between groups. RESULTS: No statistically significant differences were found between groups in terms of age, weight, waist circumference, body mass index, and dysmenorrhea (p>0.05). A significant relationship was found between the height and the degree of hirsutism in the groups (p<0.05). It was found that prolactin, total testosterone, and dehydroepiandrosterone sulfate levels were statistically significantly higher in the polycystic ovary syndrome group compared to the control group. The polycystic ovary syndrome group had hemoglobin, leukocytes, lymphocytes, neutrophils, platelets, and statistically higher ratios of total cholesterol/high-density lipoprotein, Low-density lipoprotein/high-density lipoprotein, and triglycerides/highdensity lipoprotein. No statistically significant relationships were found between homeostatic model assessment insulin resistance, neutrophilto-lymphocyte ratio, and monocyte-to-high-density lipoprotein ratio between the groups (p<0.05). There was no significant difference in systemic immune inflammation index values between the groups. CONCLUSION: Polycystic ovary syndrome patients are at risk for short-and long-term complications, and the use of the total cholesterol/high-density lipoprotein, Low-density lipoprotein/high-density lipoprotein, and triglycerides/high-density lipoprotein ratios in clinical practice during the follow-up of these patients may allow easy follow-up for patients. The health status of polycystic ovary syndrome patients can be objectively determined by tracking these outcomes at regular intervals.
Aim: The aim of this study was to evaluate the effect of epilepsy disease and the antiepileptic treatment protocol on the mother, fetus, and newborn in pregnant women, diagnosed with epilepsy and taking antiepileptic drugs. Materials and Method: 55 pregnant women who were followed up at Sivas Cumhuriyet University Faculty of Medicine, Department of Obstetrics and Gynecology between 2015 and 2020 and diagnosed with epilepsy were included in the study. Age of pregnant women, number of pregnancies, number of births, age at diagnosis of epilepsy, body mass index (BMI), smoking during pregnancy, whether they went to neurology control before pregnancy, type of seizures during pregnancy, seizures in which trimester, and frequency, AED’s used during pregnancy and treatment protocols, folic acid use in pregnancy were evaluated. Obstetric complications that occurred during the follow-up of the pregnant women included in the study and the weeks of delivery were recorded. Newborn 1.-5. min. Early neonatal problems such as Apgar scores, fetal malformations and fetal distress were evaluated. Results: The median age was found to be 26 (17-42). The median number of pregnancies is 2 (1-8). The median of the number of births is 1 (0-6). The average age of epilepsy diagnosis of the women included in the study was 15 (3-29). Thirty-four (61.9%) of the patients had generalized and 2 (3.6%) partial seizures. 19 (34.5%) of them did not have seizures during pregnancy. The average of those who developed complications during pregnancy follow-up was 43.6%, and the average of those who did not develop was 56.4%. There is a statistical difference between the number of seizures in trimesters of pregnancy and the 1st minute Apgar score (p
İlk trimester vitamin D, vitamin B12 ve ferritin seviyelerinin preeklampsi ve yenidoğan sonuçlarıyla olan ilişkisini araştırmayı amaçladık. Araçlar ve Yöntem: Çalışmaya preeklampsi (PE) tanısı almış 191 hasta ve 99 sağlıklı gebe kadın dahil edildi. Hastaların yaş, gravida, parite, beden kitle indeksi (BKI), doğum şekli, doğum kilosu, APGAR skoru, yenidoğan yoğun bakım ünitesi (YYBÜ) kabulü ve doğum haftası kaydedildi. Laboratuvar analizlerinde ilk trimester vitamin D, vitamin B12 ve ferritin düzeyleri tespit edildi. PE'siz, PE'li ve şiddetli PE'li olmak üzere üç grup ayrılarak değerlendirme yapıldı. Bulgular: BKI ölçümleri, doğum haftaları, doğum kiloları, YYBÜ kabulü değerleri arasında farklılık saptandı (p değeri sıra-sıyla= 0.003; 0.001; 0.001; 0.001). PE grubundaki bebeklerin ortalama doğum haftaları, doğum kiloları ve APGAR skorları PE'siz gruba göre düşük bulundu. PE grubundaki gebelerin sezaryen olma oranı yüksekti (p=0.001) . PE grubunun vitamin D düzeyi, PE'siz gruba göre anlamlı düzeyde düşüktü (p=0.001). Vitamin D düzeyinin PE şiddetiyle orantılı olarak azaldığı tespit edildi. PE'siz grubun B12 düzeyi, PE'li gruba göre yüksekti (p=0.001). PE'siz grubun ferritin düzeyi PE'li gruba göre düşük tespit edildi (p=0.001). Sonuç: İlk trimesterde vitamin D ve B12 düşüklüğü, ferritin yüksekliği preeklampsi öngörüsünde faydalı olabilir. Özellikle D vitamini, B12 ve demir desteğinin preeklempside perinatal morbidite ve mortaliteyi azaltacak basit ama etkili bir yaklaşım olduğunu düşünmekteyiz.
Amaç: İlk trimester lipid profilinin preeklampsi öngörüsünde faydasını ve yenidoğan sonuçlarıyla olan ilişkisini araştırmaktır. Gereç ve Yöntemler: Çalışmaya preeklampsi (PE) tanısı almış 121 hasta ve 99 sağlıklı gebe kadın dahil edildi. Çalışma retrospektif olarak dizayn edilmiştir. Hastaların yaş, gravida, parite, vücut kütle indeksi (VKI), doğum şekli, doğum kilosu, APGAR skoru, yenidoğan yoğun bakım ünitesi (YYBÜ) kabulü ve doğum haftası kaydedildi. Laboratuvar analizlerinde ilk trimester (
Objective: In addition to being a global epidemic, Coronavirus disease creates some disruptions in the health system, especially in family planning services. Our study aimed to assess the contraceptive method preferences of female patients who applied to our university hospital, their satisfaction levels, and whether their method usage had changed due to the pandemic.Material and Methods: We included 286 female patients aged 18-49 who were admitted to our obstetrics and gynecology outpatient clinic between January 2021 and April 2021 in our study. We conducted a descriptive cross-sectional study to identify women's contraceptive method preferences, complaints about the method, and usage information before and during the pandemic.Results: While 187 (65.4%) of 286 women participating in our study used modern and traditional family planning methods, 99 (34.6%) did not use any method. We found a statistically significant decrease in the use of oral contraceptives during the pandemic (p=0.041). While the number of women who did not use any method before the pandemic was 83 (29%), 99 (34.6%) women did not use any method during the pandemic.Conclusion: Family planning service is one of the foremost sexual and reproductive health services. The factors such as social distance, isolation at home, and increased stress during the pandemic have increased the need for sexual and reproductive health services. Moreover, movement restrictions and clinical closures make sexual and reproductive health services, including birth control, less accessible. All of these conditions will raise the number of erroneous, unplanned, and undesired pregnancies. In our study, the most preferred method of contraception was found to be condoms (27.3%), while the least used method was injectable contraceptive (1.4%). Clinicians should counsel women on contraception options in the event that further social distancing measures are implemented.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.